SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer

NCT06819319 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

52

Enrollment

OTHER_GOV

Sponsor class

Conditions

TNBC - Triple-Negative Breast Cancer

Interventions

DRUG: SHR-A2102 ; Adebrelimab injection

Sponsor

Henan Cancer Hospital